These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 11300612)

  • 1. Turnover of 125I-labelled tissue kallikrein following intraduodenal or intravenous administration.
    Bläckberg M; Ohlsson K
    Scand J Clin Lab Invest; 2001 Feb; 61(1):57-67. PubMed ID: 11300612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraglandular transport of 125I-glandular kallikrein in the rat submandibular salivary gland.
    Orstavik TB; Gautvik KM; Nustad K
    Acta Physiol Scand; 1980 Jul; 109(3):315-23. PubMed ID: 6905637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fate of plasma kallikrein in normal and kininogen-deficient rats.
    Kouyoumdjian M; Damas J
    Arch Physiol Biochem; 1998 Feb; 106(1):25-32. PubMed ID: 9783057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clearance and metabolism of glandular kallikrein in the rat.
    Rabito SF; Seto M; Maitra SR; Carretero OA
    Am J Physiol; 1985 Jun; 248(6 Pt 1):E664-8. PubMed ID: 3847263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, absorption, distribution and disposition of [125I]-defibrotide following intravenous or oral administration in the rat.
    Fisher J; Johnston AM; Holland TK; McCallum J; Pescador R; Mantovani M; Prino G
    Thromb Res; 1993 Apr; 70(1):77-90. PubMed ID: 8511753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution and elimination of intravenously injected urinary trypsin inhibitor.
    Jönsson-Berling BM; Ohlsson K
    Scand J Clin Lab Invest; 1991 Oct; 51(6):549-57. PubMed ID: 1767247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human kallistatin, a new tissue kallikrein-binding protein: purification and characterization.
    Wang MY; Day J; Chao L; Chao J
    Adv Exp Med Biol; 1989; 247B():1-8. PubMed ID: 2558505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue kallikrein in severe acute pancreatitis in patients treated with high-dose intraperitoneal aprotinin.
    Bläckberg M; Berling R; Ohlsson K
    Pancreas; 1999 Nov; 19(4):325-34. PubMed ID: 10547191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions in vitro and in vivo between porcine tissue kallikrein and porcine plasma proteinase inhibitors.
    Bläckberg M; Ohlsson K
    Scand J Clin Lab Invest; 1994 Dec; 54(8):643-51. PubMed ID: 7535946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine b-Hydroxylase: Determination of half-life and appearance in lymph fluid after IV injection of 125 I-DBH into rats.
    Geyer SJ; Schanberg SM
    Life Sci; 1982 Mar; 30(13):1087-100. PubMed ID: 7078347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Purification and some physico-chemical and enzymatic properties of tissue kallikrein from human urine].
    Rabinovich SE; Lobareva LS; Paskhina TS
    Biokhimiia; 1990 Sep; 55(9):1675-89. PubMed ID: 2078641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo catabolism of human kallikrein-binding protein and its complex with tissue kallikrein.
    Xiong W; Tang CQ; Zhou GX; Chao L; Chao J
    J Lab Clin Med; 1992 May; 119(5):514-21. PubMed ID: 1583408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The elimination of secretory leukocyte protease inhibitor (SLPI) from the gastrointestinal tract in man.
    Nyström M; Bergenfeldt M; Ohlsson K
    Scand J Clin Lab Invest; 1997 Apr; 57(2):119-25. PubMed ID: 9200270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, absorption, distribution and disposition of [125I]-oligotide following intravenous or oral administration in the rat.
    Fisher J; Holland TK; Pescador R; Porta R; Ferro L
    Thromb Res; 1997 Mar; 85(6):445-53. PubMed ID: 9101637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and characterization of a radioimmunoassay to measure human tissue kallikrein in biological fluids.
    Bagshaw AF; Bhoola KD; Lemon MJ; Whicher JT
    J Endocrinol; 1984 May; 101(2):173-9. PubMed ID: 6562157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clearance and distribution of acid-stable trypsin inhibitor (ASTI).
    Sugiki M; Sumi H; Maruyama M; Yoshida E; Mihara H
    Enzyme; 1989; 42(1):31-8. PubMed ID: 2776713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiolabeling, stability, and body distribution in rats, of low molecular weight polylactide homopolymer and polylactide-polyethyleneglycol copolymer.
    Bridges JF; Critchlow M; Irving MP; Purkiss SC; Taylor DC; Lloyd JB
    Biomaterials; 2000 Jan; 21(2):199-209. PubMed ID: 10632402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism of 131I-labelled human pancreatic cationic trypsin after intraduodenal administration.
    Bohe M; Borgström A; Genell S; Ohlsson K
    Digestion; 1986; 34(2):127-35. PubMed ID: 3732638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absorption studies with porcine pancreatic kallikrein in man.
    Miska W; Geiger R; Schill WB
    Agents Actions Suppl; 1992; 38 ( Pt 2)():136-43. PubMed ID: 1462822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a new tissue-kallikrein-binding protein.
    Chao J; Tillman DM; Wang MY; Margolius HS; Chao L
    Biochem J; 1986 Oct; 239(2):325-31. PubMed ID: 3643793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.